Oyewale O. Abidoye

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

Jonathan E. Rosenberg, Jean Hoffman‐Censits, Tom Powles et al. · The Lancet · 2016 · 3.7K citations · Full text

Urology, Metastatic Urothelial Carcinoma, Genitourinary Cancer +8

Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial

Arjun Vasant Balar, Matthew D. Galsky, Jonathan E. Rosenberg et al. · The Lancet · 2016 · 2.2K citations · Full text

Urology, Genitourinary Cancer, Medicine +7

IMvigor 210, a phase II trial of atezolizumab (MPDL3280A) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC).

Jean Hoffman‐Censits, Petros Grivas, Michiel Simon Van Der Heijden et al. · Journal of Clinical Oncology · 2016 · 84 citations

Immunology, Immunoediting, Pathology +20

A phase II study of lapatinib (GW572016) in recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN)

Oyewale O. Abidoye, Ezra E.W. Cohen, Stuart J. Wong et al. · Journal of Clinical Oncology · 2006 · 79 citations

Squamous Cell Carcinoma, Pathology, Phase Ii Study +17

A phase Ia study of MPDL3280A (anti-PDL1): Updated response and survival data in urothelial bladder cancer (UBC).

Daniel P. Petrylak, Thomas Powles, Joaquim Bellmunt et al. · Journal of Clinical Oncology · 2015 · 63 citations

Urothelial Bladder Cancer, Immunology, Immune Regulation +26